Dr. Phillip Shelton's practice focuses on patent prosecution and patent portfolio management in the pharmaceutical and biotech industries. His practice involves preparing and prosecuting patent applications, managing worldwide patent portfolio strategies, performing due diligence evaluations and freedom-to-operate analyses, as well as evaluating the patentability/invalidity of claims. He is also involved in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) and European Opposition procedures before the European Patent Office (EPO).
Phillip has experience with a wide range of technologies, including cell-based therapeutics (e.g, stem cells and iPS cells), gene therapy, CRISPR technology, bioengineered microorganisms, CAR-T therapies, neoantigen identification, antibody therapeutics, xenotransplantation, AAV-based therapeutics, clinical diagnostics, pharmacodynamic and diagnostic biomarkers, mitochondrial replacement therapy, and peptide therapeutics, among others. He has worked with established companies, start-ups, and research institutions.
Phillip holds a Ph.D. in molecular toxicology and a M.S. in molecular medicine from the University of Maryland. Prior to joining Jones Day, Phillip worked as a postdoctoral research associate in Jorge Moscat and Maria Diaz-Meco's lab in La Jolla, California, where he investigated the role of microRNAs and extracellular vesicles in promoting colorectal cancer metastases. Phillip has coauthored several publications and presented at international research conferences.
- April 5, 2021
Conditional Offer to Abandon Claims Does Not Constitute Waiver to Assert, PTAB Litigation Blog
- June 2020
District Courts Find PTAB Statements Constitute Disclaimer, PTAB Litigation Blog
- January 2020
Collateral Estoppel Applied by District Court Following IPR on Similar Patents, PTAB Litigation Blog
Publications Prior to Jones Day
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance, Immunity, 49(6):1132-1147
Metabolic reprogramming of the tumor microenvironment by p62 and its partners, Biochim Biophys Acta Rev Cancer, 1870(1):88-95
The Secretion of miR-200s by a PKCζ/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer, Cell Rep., 23(4):1178-1191
Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ, Cell Rep., 10(5):740-754
Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor, PLoS One, 13;8(9):e74525
The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?, FASEB J, Feb;27(2):414-23
- University of San Diego (J.D. 2022); University of Maryland (Ph.D. in Toxicology 2013; M.S. in Molecular Medicine 2009); Indiana University (B.S. in Biology 2006)
- California, U.S. District Court for the Southern District of California, and registered to practice before the United States Patent and Trademark Office